Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus IP chemotherapy for second-line small cell lung cancer
ChiCTR1800018642Phase 4Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Oct 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, irinotecan and cisplatin in small cell lung cancer (SCLC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Size of the lesions. Started Oct 2018; status: recruiting.
02
Drugs
Rivoceranibirinotecancisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR1800018642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018642.